is eteplirsen effective in non-ambulatory duchenne patients?
Published 8 years ago • 3.7K plays • Length 6:59Download video MP4
Download video MP3
Similar videos
-
9:48
the 4 year struggle to get eteplirsen to a duchenne patient
-
0:54
janet woodcock - duchenne drug review and the patients' input
-
5:30
how to talk to the fda
-
1:03:36
emerging therapies for duchenne muscular dystrophy
-
3:18
elias kouchakji, md: importance of non-ambulatory patients in dmd trials
-
1:20:12
direct access: sarepta, eteplirsen with chris garabedian (oct 2012)
-
2:35
if you want the fda's attention, get your message to where they are looking
-
11:08
experts support exondys 51
-
1:18
former ceo of sarepta discusses the current duchenne drug landscape
-
2:06:13
new england cepac: duchenne muscular dystrophy, evidence presentation
-
4:47
duchenne policy forum to optimize clinical trials
-
4:49
exondys51 should be prescribed to dmd with amenable mutations.
-
11:21
in the pipeline: restoring dystrophin - ptc therapeutics (ataluren)
-
1:33:40
new england cepac: duchenne muscular dystrophy, voting session
-
![sarepta therapeutics (eteplirsen) [ppmd's 2015 connect conference]](https://i.ytimg.com/vi/j6pVDteTyMQ/mqdefault.jpg)
14:42
sarepta therapeutics (eteplirsen) [ppmd's 2015 connect conference]
-
58:43
avi clinical trial update (3/2012)
-
2:05
duchenne parent comments on the sarepta-fda battle
-
52:23
community webinar series 2021: advancements in duchenne drug development and fda approved therapies
-
53:34
in the pipeline: dystrophin restoration (ppmd's 2021 virtual annual conference)